^
    3years
    Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. (PubMed, Cancers (Basel))
    As a result, we identified that the MEK inhibitor, PD-0325901, further enhanced the anti-proliferative and anti-clonogenic effects of gefitinib and AT7867 by inducing apoptosis. Our results suggest that the dual inhibition of the AKT and MEK pathways is a novel potential therapeutic strategy for targeting EGFR in TNBC cells.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    gefitinib • mirdametinib (PD-0325901) • AT7867